This paper reviews the existing epidemiological and clinical evidence about the relationships of non-diabetic microalbuminuria with cardiovascular risk factors such as elevated blood pressure (BP), systolic particularly, cardiac hypertrophy, adverse metabolic status, smoking habits, elevated angiotensin II levels, endothelial dysfunction, acute and perhaps subclinical inflammation. Because of that unique property of reflecting the influence of so many clinically relevant parameters, microalbuminuria may legitimately be defined as an integrated marker of cardiovascular risk, an unique profile among the several prognostic predictors available to
Introduction
Although the first descriptions of the phenomenon and its prognostic implication date back to 1974   1   and 1988 2 respectively, our knowledge of hypertensive, non-diabetic microalbuminuria results mainly from work carried out during the second half of the 1990s (see Tables 1-5) . From this perspective, microalbuminuria is to be seen as a 'new' variable under evaluation in essential hypertension, at least when compared with more studied parameters such as left ventricular hypertrophy or the reninangiotensin-aldosterone system. This review focuses specifically on the multiple and interconnected links between non-diabetic microalbuminuria 3 and a congeries of risk factors such as elevated systolic blood pressure (BP), cardiac hypertrophy, adverse metabolic status, smoking habits, elevated angiotensin II levels, endothelial dysfunction, acute and perhaps subclinical inflammation. Because of that unique property of reflecting the influence of so many and clinically relevant parameters, microalbuminuria may legit-imately be defined as an integrated marker of cardiovascular risk. This concept should, in our opinion, be more generally recognised. Urine albumin levels also predict cardiovascular morbidity and mortality and the interested reader is referred to an upcoming germane review 4 as well as to additional results from more recently published prospective studies. 5, 6 The prevalence of non-diabetic microalbuminuria
Populations at large
Several population studies have evaluated the prevalence of non-diabetic microalbuminuria with results ranging from 1 to 56% (Tables 1 and 2 ), a scatter of values due not only to the erratic day-today behaviour of urine albumin and the vagaries of urine collection, but also to systematic sources of variability of methodological and biological origin which should be taken into account.
Methodological sources of variability arise from several factors including differences in collection procedures such as daily, overnight or early morning collections, although, independent of sampling modalities, the measurement is affected by huge variability. Repeated measures help but do not resolve the problem since, even with most careful collections, albuminuria is still twice as variable as creatininuria. 4 The matter is also complicated by the use of different measurement units, either rates (g/min or mg/24 h), concentrations (mg/l) or albumin/creatinine ratios (ACR, mg/mg or mg/mmol). To facilitate comparisons, we roughly approximate the conventional boundaries of microalbuminuria (20 Use of semi-quantitative tests, which tend to overestimate urine albumin concentration, 7, 8 may, to some extent, explain the unusually high prevalence of microalbuminuria reported in some large-scale studies. [9] [10] [11] [12] Urine albumin concentrations measured in 'spot' morning collections are frequently standardised for concurrent creatinine excretion to derive ACRs. This procedure corrects for unknown urine volumes but needs differentiation of males from females in whom creatininuria is lower because of reduced muscle mass, a fact not always taken into account. 13, 14 ACRs, on the other hand, are advantageous in epidemiological studies because they are easily obtainable and highly correlated with 24-h urine albumin. 15, 16 Generally speaking, however, urine albumin measurements on timed collections, when feasible, should be preferred to concentration measures and ACRs (frequently used in the epidemiological field to correct for incomplete collections) may be strongly biased by variable hydration and skeletal muscle mass.
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Biological reasons of variability include sex, ethnic origin and clinical components. When measuring albuminuria on timed collections (g/min or mg/24 h), men tend to show higher values, 2, [17] [18] [19] possibly because risk factors for cardiovascular disease are more frequent in males or for other less obvious reasons. Ethnic origin may also account for some systematic variability since microalbuminuria in non-diabetic healthy Caucasians oscillates, with the notable exception of some Finnish communities, 20, 21 around 5% or lower as opposed to the two to three-fold higher figures in non-Caucasians, in particular American aborigines (compare Tables 1  and 2 ).
Hypertension, prevalence of additional cardiovascular diseases, glucose intolerance, diabetes mellitus in the sample under study contribute to variability, as shown by the data reported in Table  1 . For example, in spite of roughly similar rates of hypertension, the 3.5% prevalence found in a sample of apparently healthy inhabitants of a small Italian town 18 contrasts strikingly with the four to fivefold higher figures reported in non-diabetic coronary patients of the HOPE study 14 or the Horn cohort enriched with diabetic and glucose intolerant subjects. 22 

Hypertensive cohorts
Not unexpectedly, given the importance of BP levels as a biological covariate of urinary albumin excretion (UAE, see below), prevalence rates of microalbuminuria in hypertensive patients are definitely higher than in populations at large. However, large-scale surveys recruiting subjects from general practices or population screenings [23] [24] [25] [26] reported figures lower than those series assembled in tertiary referral centers (see Table 3 ), most likely because of inclusion of more patients with mild and white-coat hypertension (about 30% in the HAR-VEST study, 24 a condition in which the prevalence of microalbuminuria does not differ from normotension.
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Microalbuminuria and cardiovascular risk factors
BP levels
Practically all studies so far available have shown a trend to higher BP in micro-than normoalbuminuric hypertensives (Table 3) with statistically significant positive intraindividual positive correlations between BP and albuminuria. The evidence has been obtained in white-coat, borderline, mild-moderate, severely hypertensive patients, both never-treated, temporarily untreated, treated, elderly or younger, and by assessing BP either sphygmomanometrically or by ambulatory monitor- ing. Ambulatory BP monitoring also allowed to show greater UAE in hypertensives in whom nocturnal BP falls do not occur or are less evident (see Pedrinelli 3 for a review). Overall, the data support the concept of a relationship between microalbuminuria and transmission of elevated pressure levels to the glomerulus in the framework of a generalised rise in capillary pressure in hypertension. 29 Systemic BP may exert some modulating influence on albuminuria even in normotensive subjects 13, [30] [31] [32] and perhaps in normoalbuminuric hypertensive patients. 33 The reduction of UAE in a matter of days during pharmacological hypotension 34 confirms in full the importance of functional components, since structural arteriolar or glomerular hypertensive lesions would not revert so rapidly. Likely, altered functional mechanisms coexist with nephroangiosclerotic alterations particularly in the more severe and longer standing cases, 35 but no bioptic study has so far investigated the relative contribution of the two factors in the genesis of hypertensive microalbuminuria. The importance of elevated perfusion pressure is strengthened by the reduction of albuminuria obtained by antihypertensive drugs with a different mechanism of action including beta-adrenoceptor blockers, diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors and the newer angiotensin II receptor antagonists.
32,36-41 ACE inhibitors, however, usually proved more effective in reducing UAE in head-to-head comparisons with calcium channel blockers in rather small and relatively short-term clinical studies.
42-44
The close relationship of UAE with BP is likely to represent the reflection of a long-term haemodynamic overload, since higher UAE values are associated with greater cardiac mass (see below) and increased minimal forearm vascular resistance, 45 two indices of the long-term cardiovascular restructuring process induced by hypertension. 46 Given this, it must be recognised that, albeit statistically significant, correlations with BP levels explain only a minor portion (from 15 to 30% at best) of the overall UAE variability. That behaviour is closely consistent with the nature of microalbuminuria as an integrated risk marker sensitive to several and disparate factors such as cardiac hypertrophy, metabolic status, and smoking habits. As reviewed in detail elsewhere, 4 microalbuminuria also reflects endothelial dysfunction, and the recently reported reduction of both endothelium-dependent and independent components of flow-mediated dilation of the brachial artery suggests that microalbuminuria might reflect a non-specific endothelial perturbation more than a specific defect of nitric-oxide mediated vasodilation. 47 Elevated systolic and pulse pressure and microalbuminuria: UAE tends to show a stronger association with systolic than diastolic BP. In addition, recent data in elders with systolic hypertension, 48 hypertensives with atherosclerotic vascular disease 49 or not 50 and even clinically healthy subjects 31 have substantiated an association of microalbuminuria with wider pulse pressure (PP), a strict correlate of systolic BP. A disproportionate rise in systolic BP accompanied by a more or less evident widening of PP is frequently apparent not only in series restricted to hypertensive patients (see data in Table 3 ) but non-diabetic populations as well. For example, a rough recalculation of PP values from the PRE-VEND 51 and HOPE 14 samples gives 62 vs 53 and 63 vs 57 mm Hg in the presence and absence of microalbuminuria respectively. Elevated systolic BP was also the best predictor of microalbuminuria in some prospective studies. 52, 53 Since systolic and pulse pressure predict cardiovascular disease in hypertension, 54 and both reflect reduced arterial compliance and a more advanced atherosclerotic process, 55 the data might imply a direct connection between microalbuminuria and macro-and microvascular disease (see Jensen 56 for a review). However, according to our results, they more likely reflect a direct damaging impact of either wider PP, elevated systolic BP, or both on the kidney.
4,49,57-59
High-normal albuminuria and increased cardiovascular risk: An interesting and emerging issue is high-normal albuminuria (somewhere between 8-15 g/min or 15-30 mg/24 h) as a condition of increased cardiovascular risk, consistent with the nature of UAE as a continuous variable, rather than a dichotomous categorisation carved out of a range of values. This notion is strongly supported by the results of four prospective cohort studies showing increased cardiovascular risk in presence of ACR well below 2 mg/mmol, the canonical limits for microalbuminuria. In the Copenhagen City Heart Study, an ACR Ͼ0.65 mg/mmol, the upper decile of that distribution, carried an independent 2.3-fold higher relative risk of cardiovascular events over a 11 to 12 year follow-up. 60 On the same lines, prospective data from the 5545 non-diabetic subjects of the HOPE cohort confirmed the existence of a continuous relationship between albuminuria and cardiovascular events (a composite end-point including myocardial infarction, stroke or cardiovascular death) extending as low as 0.5 mg/mmol. 5 A recent cohort study carried out in postmenopausal Dutch women reported a significantly greater relative risk for cardiovascular death above ACRs of 1 mg/mmol. 6 In hypertensive subjects, finally, Jensen et al 61 reported an independent and elevated risk (RR: 5.4, 95% CI: 1.8-15.7) for incident cardiac events (fatal and non-fatal myocardial infarction, angina, ischaemic heart disease) in apparently uncomplicated, non-diabetic hypertensive patients with ACR Ͼ1.07 mg/mmol. This important new concept, reminiscent of similar developments in diabetes, 62 may perhaps lead to adopt lower limits for diagnosing microalbuminuria in the near future. (Table 4) . Not surprisingly, therefore, essential hypertensive patients with microalbuminuria frequently showed either mild fasting hyperglycaemia or a hyperglycaemic response to oral glucose loading. [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] Since a worse glucose tolerance is part of the so-called metabolic syndrome X, 73 slight elevations in UAE were also associated with its typical phenotypes, ie, hyperinsulinaemia, [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] 74 insulin resistance, 67, 68 high triglycerides and low high-density lipoprotein (HDL), 25, 75, 76 overweight-obesity 18, 77, 78 and BP sensitivity to increased sodium intake. 79 Increased concentrations of total and low-density lipoprotein (LDL)-cholesterol sometimes reported in hypertensive patients with microalbuminuria 3 have raised the intriguing possibility of a link between microalbuminuria and atherogenic lipids unrelated to the trait of the syndrome X, but the results of large-scale studies 14, 18 seem to contradict that possibility.
Hyperinsulinaemia and insulin resistance as causes of microalbuminuria:
Some discussion in recent years has raised the hypothesis of hyperinsulinaemia and insulin resistance as direct causes of hypertensive microalbuminuria. 67, 69 Advocates of the theory propose several speculative mechanisms including altered glomerular permeability to albumin by insulin, 80 though this is disputed. 81 Common genetic backgrounds may also predispose to both insulin resistance, increased albuminuria 82, 83 and eventually diabetes, an interesting hypothesis supported by some prospective studies. 21 Genetic factors may explain the association with erythrocyte Na-Li counter-transport 84, 85 (a geneticallydetermined cell membrane ion transport mechanism and a mode of operation of the sodium-hydrogen [Na 86 but even this point is controversial. 87 As a matter of fact, several pieces of evidence may suggest only an indirect or a coincidental association between hyperinsulinaemia and subclinical renal damage in non-diabetic, hypertensive subjects. In population studies, for example, Winocour et al 88 found an inverse relationship (ie, the opposite of what expected), Zavaroni et al), 89 Jager et al 90 and NGT, normal glucose tolerance; IGT; impaired glucose tolerance.
Jensen et al 91 a dissociation, and Hodge et al 92 a week and statistically nonsignificant positive association between albuminuria and insulin resistance in normo-and hypertensive non-diabetic subjects. Furthermore, the association did not hold or strongly weaken after accounting for BP levels, 93 body size 68 and plasma glucose. 72, 75, 94 Glucose-stimulated insulin levels, a surrogate end-point of insulin resistance, showed poor correlation with urine albumin or none at all in populations at risk of cardiovascular disease 20, 95 or in essential hypertensive patients.
96-99
The renin-angiotensin system
Increased activity of the renin-angiotensin system is a significant risk factor for the development of organ damage and cerebral and cardiovascular accidents in hypertensive patients 100 and albuminuria seems to be associated with hyper-reninaemia and, therefore, elevated angiotensin II. 101 Interestingly, many patients with microalbuminuria may be genetically predisposed to abnormally high levels of angiotensin II, by virtue of being DD polymorphic for the ACE gene, 102, 103 a condition that involves increased circulating (and perhaps also tissue) levels of converting enzyme. 104 Moreover, a greater frequency of unfavourable genotype combinations for key factors in the renin-angiotensin system (angiotensin II converting enzyme, angiotensinogen, the AT1 receptor for angiotensin II) has recently been documented in microalbuminuric patients. 105 Further, albeit indirect, evidence for a role of angiotensin II in microalbuminuria development is represented by the stronger anti-albuminuric effect exerted by the ACE inhibitors as compared with other antihypertensive drugs. [42] [43] [44] Cigarette smoke Similar to type 1 and 2 diabetics, 106, 107 non-diabetic smokers, hypertensive or not, tend to excrete more albumin ( Table 5 ). The first report by Gosling et 114 and may expose to higher risk of morbid events when coexisting with elevated UAE.
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Microalbuminuria and hypertensive target organ damage
Left ventricular hypertrophy
Since the very first descriptions, [115] [116] [117] [118] the association between increased UAE and left ventricular hypertrophy, either by ECG or echographically, has been almost universally confirmed, 3, 12, 14, 49, 50, 76, [119] [120] [121] [122] [123] with a notable exception in patients with stage I hypertension and a high prevalence of white coat hypertension. 24 This discrepant behaviour adds value to the combined determination of the two markers of renal and cardiac involvement to stage risk during the initial phase of hypertension. Echocardiography has also shown a disproportionate rate of concentric type hypertrophy 50, 123 -the left ventricular condition with the most unfavourable prognosis, 124 and a trend to reduced left ventricular contractility. 123 This latter finding adds a new facet to the unfavourable clinical profile associated with hypertensive microalbuminuria.
It is important to note that the association between cardiac mass and UAE not only reflects an abnormal pressor overload, but holds even after accounting for BP, as shown in recent works. 14, 49, 50 This behaviour, again consonant with the nature of microalbuminuria as an integrated risk marker, suggests direct influences of the heart on UAE. An obvious candidate to that role is the atrial natriuretic peptide (ANP), a natriuretic and albuminuric hormone 125 produced in greater quantities by a hypertrophic ventricle, 126 a plausible hypothesis needing confirmation, however. Whatever the case, pressureindependent links with left ventricular hypertrophy, in itself a marker and/or risk factor of hypertensionrelated clinical events above and beyond BP levels, 127 should be kept in mind to interpret the predicting power of microalbuminuria for morbidity and mortality. 
Renal dysfunction
In contrast to diabetic patients in whom microalbuminuria is frequently accompanied by hyperfiltration and anticipates a decline in renal function, 128 hypertensive microalbuminuria is characterised by unchanged glomerular filtration rate, reduced renal plasma flow, increased filtration fraction, elevated vascular resistance [129] [130] [131] [132] and exhaustion of the renal functional reserve. 133 Recent cross-sectional reports in non-diabetic populations 51 do, however, suggest a more complicated picture. High-normal albuminuria rather than microalbuminuria may, in fact, represent the initial and easily missed stage associated with hyperfiltration, followed by normalisation of glomerular filtration rate in the presence of microalbuminuria. Progression to macroalbuminuria might then herald a decline in renal function during the course of hypertensive nephropathy, but this tempting profile is purely speculative since no follow-up study has ascertained such a temporal evolution. A still unanswered question is whether microalbuminuria predicts a decline in kidney function, a likely hypothesis were it not for the strong association of UAE with elevated systolic BP, an established renal risk factor, 134 and with smoking as an emerging one. 53, 135 Still, very few studies addressed specifically the issue with inconsistent results 136, 137 and the relationship between essential hypertension itself, the renal prognostic significance of hypertensive microalbuminuria and nephroangiosclerosis remains uncertain.
138,139
Should we be routinely measuring albuminuria to screen for microalbuminuria?
Convincing evidence has shown an association of elevated UAE in essential hypertension with higher systolic and pulse pressure levels, left ventricular hypertrophy-through pressure-dependent and independent mechanisms, overweight, glucose intolerance and other phenotypes of the metabolic syndrome X, smoking, genetically determined elevated renin-angiotensin II levels and/or activity. Furthermore, high-normal albuminuria, besides sharing a similar adverse cardiovascular and metabolic risk pattern with microalbuminuria, may be characterised by hyperfiltration possibly conducive to glomerular hypertension and eventually renal insufficiency. In addition, the consistent body of knowledge showing independent connections between albuminuria and cardiovascular morbidity and mortality [4] [5] [6] should, in our opinion, prompt more widespread screenings in essential hypertensive patients, similar to the approach advocated for other risk markers in hypertension such as left ventricular mass. 156 Thus, microalbuminuria, an integrated marker of cardiovascular risk, may be particularly effective to identify patients at higher absolute risk in whom preventive treatment will be more beneficial than patients with a lower absolute risk. Reduction of subclinical albuminuria as such may also represent a clinically relevant end-point worth being actively pursued by pharmacological treatment. Although no evidence is available in this regard, the antiproteinuric effect of ACE inhibitors Journal of Human Hypertension or angiotensin II receptor blockers paralleled a better renal and cardiovascular prognosis in hypertensive patients with renal failure, either diabetic 157 or not. 158 The issue reminds, to some extent, the debate about cardiac hypertrophy, in which earlier hypotheses 159 were a long time being proven, 160 although, hopefully, we will have to wait less time to get an answer about non-diabetic microalbuminuria.
